{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-085580","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2023-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.240297+00:00","generated_at":"2026-06-12T22:12:18.486454+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Passage Bio board change: director resigns, new director Dolan Sondhi appointed","bullets":["Thomas Woiwode resigned from Board and Compensation Committee effective July 26, 2023; no disagreement cited.","Board appointed Dr. Dolan Sondhi as Class II director effective July 27, 2023, filling a vacancy.","Dr. Sondhi is Professor of Research in Genetic Medicine at Weill Cornell, with gene therapy expertise.","Received non-incentive stock options for 48,000 shares vesting over three years under 2020 Equity Plan.","Also appointed to the Nominating and Corporate Governance Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-085580","json":"https://secwatch.observer/filing/0001104659-23-085580.json","markdown":"https://secwatch.observer/filing/0001104659-23-085580.md","text":"https://secwatch.observer/filing/0001104659-23-085580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923085580/0001104659-23-085580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923085580/tm2322324d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T22:12:18.486454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4bb279d97d","claim":"Dolan Sondhi was appointed as Director at Passage BIO, Inc..","evidence_excerpt":"the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “ Governance Committee ”), appointed Dr. Dolan Sondhi as a Class II director to fill a Board vacancy","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923085580/0001104659-23-085580-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d1152d355b","claim":"Thomas Woiwode resigned as Director at Passage BIO, Inc..","evidence_excerpt":"Thomas Woiwode, Ph.D., notified Passage Bio, Inc. (the “ Company ”) of his decision to resign from the Company’s Board of Directors (the “ Board ”), including from the Compensation Committee of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923085580/0001104659-23-085580-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}